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Background (and Purpose). The aim of this study was to investigate the importance of including the measurement of bone mineral
density (BMD) in reliable fracture risk assessment for women diagnosed with early nonmetastatic breast cancer (EBC) before AI
treatment if zoledronic acid is not an option. Material and Methods. One hundred and sixteen women with EBC were included
in the study before initiating AI treatment. Most participants were osteopenic. The 10-year probability of hip fracture and major
osteoporotic fracture was calculated with and without BMD based on clinical information collected at baseline using the fracture
risk assessment (FRAX) tool. To compare data, the nonparametric tests were used. Results. There was a significant difference
(p<0.001) in the number of high-risk and low-risk FRAX score of hip fracture between before and after including BMD values.
The high-risk category decreased by 50.9%, while the low-risk category increased by 42.9%. In FRAX score of major osteoporotic
the findings were similar (p<0.001):The high-risk andmoderate-risk category decreased by 70.4% and 4.9%, respectively, while the
low-risk category increased by 43.8% when including BMD value. When stratified by age, patients aged 65 years or older were at a
significantly (p<0.001) higher risk of suffering a hip or major osteoporotic fracture, highlighting the importance of including BMD
measurements in this age group. Conclusions. Our data support that DXA scanning of women with EBC should be performed to
avoid overestimation of osteoporosis before AI treatment. It is particularly important in patients older than 65 years of age and
when zoledronic acid is not an option.
1. Introduction
Breast cancer treatment has improved in Europe over the
past decades with an 82% 5-year age-adjusted relative sur-
vival for women diagnosed between 2000 and 2007 [1].
However, breast cancer is still the number one cause of
cancer-related death in Europe, although lung cancer as
the number two cause of death in Europe is the most
frequent cause of cancer death in Denmark. The currently
expected levels of survival are improved in part due to breast
cancer screening programs providing earlier detection and
new improved adjuvant therapy options [2]. The decreased
mortality rate is mainly seen among younger patients
[2].
After initial treatment of breast cancer by surgery patients
are often offered adjuvant treatments such as radiotherapy,
chemotherapy, HER2-directed treatment, and antihormonal
therapy for patients with estrogen receptor positive disease
(approximately 75%). Adjuvant antihormonal treatment is
for premenopausal patients usually 5-10 years on tamoxifen
and for postmenopausal patients five years on the aromatase
inhibitor (AI) [2].The AIs improve both disease-free survival
Hindawi
Journal of Osteoporosis
Volume 2018, Article ID 4636028, 6 pages
https://doi.org/10.1155/2018/4636028
2 Journal of Osteoporosis
(DFS) and overall survival (OS)(OS compared with tamox-
ifen) [3].
Patients on therapy with tamoxifen do not increase their
risk of bone loss whereas the AI-induced ovarian suppression
of estrogen production increases the risk of bone loss and
fracture [4]. It is widely known that women undergoing
therapy with AI are recommended for supplementation
with calcium and vitamin D. Thus far, a dual energy X-
ray absorptiometry (DXA) scanning prior to AI therapy is
recommended to avoid overestimation of osteoporosis.
Since 2015 it is recommended to administer zoledronic
acid, a bisphosphonate, along with AI in early nonmetastatic
breast cancer (EBC) [5]. Zoledronic acid is effective in frac-
ture prevention in postmenopausal womenwith osteoporosis
[6]. It is further known from the meta-analysis published
by the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) that some antineoplastic effect is gained from
zoledronic acid [5]. Based on this double effect, it might be
questioned if DXA-scanning is relevant at the beginning of
treatment initiation with AI and zoledronic acid.
Since many breast cancer patients encounter treatment-
related distress and findings indicate that women offered a
DXA-scan refuse because of this stress, tools to support clini-
cal decision-making regarding the treatment of patients with
low bone mass are indeed needed [7, 8]. The risk assessment
tool, fracture risk assessment (FRAX), has been developed
by the University of Sheffield and is widely used in the
clinic [9]. FRAX integrates clinical risk factors: country, age,
sex, weight, height, previous fracture, family fracture history,
smoking, glucocorticoid treatment, rheumatoid arthritis, dis-
ease strongly associated with osteoporosis, and alcohol intake
with or without assessment of bone mineral density (BMD)
at the femoral neck, to evaluate the 10-year probability of
hip fracture and major osteoporotic fractures (clinical spine,
forearm, hip, or shoulder fracture).
In the present study, we evaluated the importance of age
and BMD in reliable fracture risk assessment in a cohort of
women diagnosed with EBC.
2. Methods
The target group for the present study was women diag-
nosed with EBC. In total, all 133 diagnosed women were
recruited from May 2016 to May 2017 at the Department of
Endocrinology, Rigshospitalet, Copenhagen, Denmark, for
further evaluation. Twelve women were excluded due to
previously diagnosed osteoporosis (T-score < -2.5) and/or
ongoing treatment with antiresorptive medication (e.g.,
Alendronate), and five women were excluded due to missing
data, resulting in a total of 116 women. All participants were
subject to routine examination, anthropometric and BMD
measurements.
2.1. Bone Mineral Density. BMDs were measured at the
lumbar spine (LS) (the mean of L2-L4), femoral neck (FN),
and total hip (TH) on both sides. DXA accurately determines
two-dimensional BMD (g/cm2) and detects patients with
fragile bones who are at an increased risk of incurring
osteoporotic fractures [10].
The BMDs of LS (L2–L4) and both hips (TH and FN)
were routinely measured using DXA (Hologic DiscoveryTM
QDR Series scanner), and the trabecular bone scores were
calculated afterward (TBSiNsightTM version 1.9.2.1, Med-
Imaps). Skeletal sites with metal implants were excluded.
The same laboratory technician performed all analyses.
The calibration was performed following the standard proce-
dure. According to the manufacturer, the CV (coefficient of
variation) of the total BMD is approximately 1% Europe H.
Hologic Osteoporosis Assessment. Reference Manual. 2006;
Document No. Man-00214.
2.2. Biochemistry. All blood samples were routinely obtained
via venipuncture in the antecubital vein and processed at
the central laboratory at Rigshospitalet, Denmark, for future
analysis of the plasma concentrations of free calcium-ion,
25-OH vitamin D, parathyroid hormone, serum phosphate,
alkaline phosphatase, bone-specific alkaline phosphatase,
procollagen, and osteocalcin to ensure that no other bone
disease or other disease was present.
2.3. FRAX. The 10-year probability (FRAX scores) of hip
fracture or major osteoporotic fracture with or without BMD
was calculated by fracture risk assessment tool country-
specific for Denmark on the official website (https://www
.sheffield.ac.uk/FRAX/) based on a participant’s risk at the
time of the DXA examination.
FRAX score of hip fracture ≥ 3% was defined as a high-
risk category, and vice versa: if the score was below 3%,
it was categorized as low-risk. Meanwhile, FRAX score of
major osteoporotic fracture ≥ 20% was defined as a high-risk
category, 10-19% as a moderate category, and <10% as a low-
risk category [11].
2.4. Statistical Analysis. The statistical package for the social
sciences (SPSS, version 24.0, IBM Corp., Armonk, NY, USA)
was used for all statistical analyses. The nonparametric test
was drawn to investigate differences between the FRAX score
without BMD value and the FRAX score with BMD value. A
p value ≤ 0.05 was considered statistically significant.
3. Results
The baseline clinical characteristics of the participants are
presented in Table 1. The mean age was 64.1±11.2 years and
the median was 64 years. The average LS, TH, and FN T-
scores were in the osteopenic range (T-score between -1.0 and
-2.5). The specific BMD measures are presented in Table 2.
One participant was excluded due to incomplete data. As
shown, only 2.6%of the participantswere classifiedwithin the
normal range when evaluating BMD at all sites. Osteopenia
was seen in 64.4% (BMD T-score below -2.5) and 33% had
osteoporosis (BMD T-score less than -2.5) in one or more
sites.
Table 3 shows the 10-year probability of suffering a hip
fracture. As shown, when adding BMD measurements to
the FRAX score calculation, the number of patients in the
high-risk category was reduced from 53 to 26 patients, a
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Table 1: Baseline characteristics of the participants.
Characteristics (n=116)
Age (years) 64.1 ± 11.2
Height (cm) 164 ± 7
Weight (kg) 67.1 ± 13.2
BMI (kg/m2) 24.8 ± 4.4
BMD LS (g/cm2) 0.997 ± 0.167
T-Score LS -1.6 ± 1.3
BMD left TH (g/cm2) 0.806 ± 0.108
T-Score left TH -1.6 ± 0.8
BMD right TH (g/cm2) 0.817 ± 0.103
T-Score right TH -1.5 ± 0.9
BMD left FN (g/cm2) 0.778 ± 0.111
T-Score left FN -1.6 ± 0.8
BMD right FN (g/cm2) 0.773 ± 0.145
T-Score right FN -1.6 ± 0.8
Data are presented as mean ± SD.
LS: lumbar spine; TH: total hip; FN: femoral neck.
statistically significant decrease (relative risk reduction) of
50.9% (p<0.001).The low-risk category increased by 42.9%.
Table 4 presents the calculated 10-year probability of a
major osteoporotic fracture with and without the BMDmea-
surement included. When including BMD measurements in
the FRAX major score calculation, the number of patients
in the high-risk category significantly decreased by 70.4%
from 27 to 8 patients (p<0.001), whereas the moderate risk
category decreased by 4.9% from 41 to 39 patients. The low-
risk category increased accordingly by 43.8% from 48 to 69
patients.
Tables 5 and 6 show the FRAX estimates with and without
FN BMD included and stratified by age. As shown, when
based on FRAX scores without the inclusion of FN BMD,
patients aged 65 years or older were estimated to have a
much higher risk of suffering a hip fracture and a major
osteoporotic fracture than younger patients. Thus, 90.4% of
the patients ≥65 years of age were in the high-risk category
for hip fracture, compared to only six patients (9.4 %) in the
lower age group, as shown in Table 5.
However, when including FN BMD measurements in
the FRAX assessment, we observed a significant (p<0.001)
decrease of 24 patients (51.1%) in the high-risk group among
patients ≥65 years of age. For the patients <65 years of
age (n=64) the trend was similar; there was a decrease in
proportion by 50% from 6 to 3 patients, but the change was
not statistically significant (p=0.453) since the low-risk group
only changed 5.2% from 58 to 61 patients.
The same pattern was seen when calculating risk of major
osteoporotic fracture, where all patients ≥65 years of age
(n=52) qualified into the moderate- (n=25, 48.1%) or high-
risk category (n=27, 51.9%), whereas none of the younger
patients qualified into the high-risk category, 16 (25.0%) into
the moderate, and 48 (75.0 %) into the low-risk category, as
shown in Table 6.
Including FN BMDmeasurements in the risk assessment,
a significant (p<0.001) decrease of 19 patients (70.4%) in
the high-risk group among patients ≥65 years of age was
seen. The moderate-risk category increased by eight patients
(32%) and the low-risk category became 11 patients. When
including FN BMD measurements for patients <65 years
of age the moderate risk category decreased significantly
(p=0.008) by ten patients (62.5%) and the low-risk group
increased accordingly.
From the statistical analysis, there were highly and clin-
ically relevant significant differences (p value <0.001) in the
above FRAX scores between the two age groups.
4. Discussion
Our data demonstrate that the average estimates of fracture
risk appear to be higher when BMD measurement was not
included in the FRAX calculation in EBC women before
starting AI treatment. The treatment with AI would even
further increase the risk of misjudgment as AI treatment
is not included in the FRAX algorithm. The results are in
accordance with other studies showing that risk estimates
without BMD are not as accurate in predicting fractures as
FRAX calculated with BMD [12, 13]. In a newly published
paper by Hamdy et al. they showed that FRAX calculated
without BMDdoes not correctly identify Caucasianmenwith
BMD evidence of osteoporosis [14]. The same observation
might be expected if evaluated in postmenopausal women
although not yet investigated.
Identification and treatment of EBC patients at high risk
of sustained fractures based on the presence of clinical risk
factors such as AI treatment are clinically relevant. However,
assessment disregarding BMD may lead to a number of
patients wrongly evaluated with high risk, who will be
unnecessarily treated with medications that affect BMD but
do not alter the underlying risk factors.
Our data shows that the number of EBC patients at
fracture risk seems significantly lower than that calculated by
FRAX without including BMD. In addition to this observa-
tion, the evidence of the use of FRAX in EBC is very sparse.
Leslie et al. [15] studied 36,730 women and 2,873 men, 50
years of age and older, from Manitoba, Canada, and showed
that a FRAX designation of the high risk of fracture is com-
monly associated with a densitometric diagnosis of osteo-
porosis. In accordance with their conclusions, the results of
our study demonstrate that the majority (65.4%) of patients
with a FRAX designation of “high-risk” of any hip fracture
over 10 years and all patients (100%)with a FRAX designation
of “high-risk” of anymajor osteoporotic fracture over 10 years
had at least one T-score measurement of -2.5 or lower if we
include the BMD values in FRAX evaluation. Conversely,
if we do not include the BMD values in FRAX evaluation,
only 39.6% (n=21) of 53 patients with 10-year probability of
hip fracture and 44.4% (n=12) of 27 patients with the 10-
year probability of major osteoporotic fracture had at least
one T-score measurement of -2.5 or lower.This means FRAX
calculation without BMD values in postmenopausal women
diagnosed with EBC was overestimated.
For the correct FRAX estimate, FN data are needed
[https://www.sheffield.ac.uk/FRAX/]. However, it has previ-
ously been shown that even measurements of left hip vs. right
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Table 2: BMDmeasures at spine, total hip, and femoral neck.
BMD Risk Category Spine (n=115) Left Hip
Combined Spine &
Left Hipa,b,c (n=115)
p value between the
groups∗Total Femoral (n=115) Femoral Neck (n=115)
Normal (WHO
criterion [T-score ≥-1]) 29 (25.2%) 31 (26.9%) 32 (27.8%) 3 (2.6%)
Osteopenia (WHO
criterion [T-score
between -1 and -2.5])
58 (50.4%) 70 (60.9%) 67 (58.3%) 74 (64.4%) <0.001
Osteoporosis (WHO
criterion [T-score
≤-2.5])
28 (24.4%) 14 (12.2%) 16 (13.9%) 38 (33.0%)
Data presented as n (%).
∗Statistical testing across group using Friedman test.
aCombined BMD LS and left TH vs BMD TS alone, p value <0.001 (post hoc Wilcoxon test).
bCombined BMD LS and left TH vs BMD left TH alone, p value <0.001 (post hoc Wilcoxon test).
cCombined BMD LS and left TH vs BMD Left FN alone, p value <0.001 (post hocWilcoxon test).
Other pairs which are not mentioned are not statistically significant.
Table 3: The 10-year probability of hip fracture. Without vs with using BMD on calculation.
FRAX Score of hip fracture
category Without BMD (n=116) With BMD (n=116)
p value between FRAX Score
without using BMD and with
BMD∗
Low-risk (≤ 3%) 63 (54.3%) 90 (77.6%)
<0.001
High-risk (> 3%) 53 (45.7%) 26 (22.4%)
Data presented as n (%).
∗McNemar test.
Table 4: The 10-year probability of major osteoporotic fracture. Without vs with using BMD on calculation.
FRAX score of major osteoporotic
fracture category Without BMD (n=116) With BMD (n=116)
p value between FRAX Score
without using BMD and with
BMD∗
Low-risk (<10%) 48 (41.4%) 69 (59.5%)
<0.001Moderate-risk (10-20%) 41 (35.3%) 39 (33.6%)
High-risk (>20%) 27 (23.3%) 8 (6.9%)
Data presented as n (%).
∗Wilcoxon test.
hip affect the risk assessment, as up to a 9%difference in BMD
has been reported betweenhips [16]. Taking this into account,
it could be questioned whether the FRAX calculation should
use the lowest femoral neck BMD measurement to increase
the validity of FRAX.
Our data show a significant and clinically relevant differ-
ence in both the FRAX scores, i.e., an estimate of the risk
of hip fracture and major osteoporotic fractures, between
including and excluding BMD values. Due to this significant
difference, the use of FRAX risk assessment without the
inclusion of BMD data cannot be recommended in patients
with EBC as FRAX overestimates the fracture risk, making
the BMD inclusion highly clinically important in these
patients. Our observations in postmenopausal EBC patients
are in contrary to the study of Gadam et al. [17] who found
identical fracture risk predictions with or without BMD
included in the FRAX calculation in healthy postmenopausal
women aged 50 years or older. It is possible that our EBC
patients might differ from healthy postmenopausal women.
However, EBC women evaluated before AI treatment might
only differ due to surgery and chemotherapy treatment as no
complications are found in our patient group. Therefore the
observed difference between the present study and the study
by Gadam et al. [17] is surprising.
Our results also highlight the importance of age, as we
report a clinically relevant significant difference between age
groups. The FRAX risk assessment in our study is highly
influenced by age, which is in alignment with the data by
the National Osteoporosis Group [18] and Gadam et al.
[17]. However, Gadam et al. demonstrated that, in healthy
postmenopausal women, age was the only significantly dif-
ferent risk factor between those with identical and different
predictions [17].
Our findings support the study by Gourlay et al. [19]
involving 4,957 postmenopausal women with normal BMD
or mild osteopenia, which encouraged an increase in screen-
ing interval of BMD in postmenopausal women according
to their BMD values. The FRAX score can be used as a
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Table 5: The 10-year probability of hip fracture stratified by age.
FRAX Scores of Hip Fracture w/o BMD
(n=116)
FRAX Scores of Hip Fracture w/ BMD
(n=116)
Low-risk High-risk Low-risk High-risk
Age group∗ <65a (n=64) 58(90.6) 6(9.4) 61(95.3) 3(4.7)
≥65b (n=52) 5(9.6) 47(90.4) 29(55.8) 23(44.2)
Data presented as n (%).
∗Statistical testing between the age groups using Chi Square test with Yates correction p <0.001.
aFRAX scores of hip fracture without BMD vs with BMD in below 65 years. p = 0.453 (McNemar test).
bFRAX scores of hip fracture without BMD vs with BMD in 65 years and above. p <0.001 (McNemar test).
Table 6: The 10-year probability of major osteoporotic fracture stratified by age.
FRAX Scores of Major osteoporotic w/o BMD
(n=116)
FRAX Scores of Major osteoporotic w/ BMD
(n=116)
Low-risk Moderate risk High-risk Low-risk Moderate risk High-risk
Age group∗ <65a (n=64) 48(75.0) 16(25.0) 0(0.0) 58(90.6) 6(9.4) 0(0.0)
≥65b (n=52) 0(0.0) 25(48.1) 27(51.9) 11(21.2) 33(63.5) 8(15.4)
Data presented as n (%).
∗Statistical testing between the age groups using Chi Square for proportion (Pearson Chi Square) in group without BMD, Chi Square for trend test and Mann-
Whitney test in group with BMD, p <0.001.
aFRAX scores of major osteoporotic fracture without BMD vs with BMD in below 65 years. p = 0.008 (Wilcoxon test).
bFRAX scores of major osteoporotic fracture without BMD vs with BMD in 65 years and above. p <0.001 (Wilcoxon test).
screening instrument in postmenopausal women, and if the
score reveals an increased risk for osteoporotic fracture, then
a DXA scan can be acquired to get baseline BMD data
preceding the treatment. The same should be recommended
for EBC patients.
The standard care of EBC patients in Denmark now
includes zoledronic acid treatment every six months for four
years during AI treatment. The treatment is not based on
bone loss protection but as adjuvant antineoplastic treatment
of BC based on the study of the Early Breast Cancer Trialists’
Collaborative group [5]. Zoledronic acid is very well known
as the antiresorptive treatment of postmenopausal bone loss
reducing the risk of bone fractures. However, due to side
effects or to other unknown reasons, several EBC patients
refuse zoledronic acid treatment. To avoid overestimation of
the fracture risk the BMD evaluation and FRAX calculation
may be highly recommended before other treatment options
are considered in these cases. The algorithm of Hadji P et al.
is therefore still recommended [4].
Without knowing the true or actual fracture in our
small cohort of patients, we cannot determine which of the
estimates of risk is more correct. This is the limitation of the
present study.
5. Conclusion
Our data support that, before AI treatment, DXA screen-
ing of patients suffering from EBC should be performed
for the correct estimate of fracture risk assessment. This
is particularly important in patients older than 65 years
of age and when zoledronic acid treatment is not an
option.
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